The board of directors of Shanghai Junshi Biosciences Co., Ltd. announced that TopAlliance Biosciences Inc., a subsidiary of the Company has submitted an investigational new drug application for a specific anti-TIGIT monoclonal antibody injection to the US Food and Drug Administration and such application has been accepted. The Company will commence the clinical trial of TAB006/JS006 in the US upon obtaining formal approval from the FDA. Relevant information is as follows: ABOUT TAB006/JS006 INJECTION: TAB006/JS006 is a specific anti-TIGIT monoclonal antibody injection developed independently by the Company. According to the results of pre-clinical studies, TAB006/JS006 can specifically block TIGIT-PVR inhibitory pathway, stimulate the activation of killing immune cells to secrete tumor killing factors. TIGIT (T cell immunoglobulin and ITIM domain) is an emerging inhibitory receptor shared by NK cells and T cells, which can bind to PVR receptors highly expressed on tumor cells to mediate inhibitory signals of immune responses, thereby directly inhibiting the killing effect of NK cells and T cells on tumor cells. The effect is similar to the inhibitory effect of PD-1 on T cells. A number of pre-clinical trial results show that anti-TIGIT antibody and anti-PD-1/PD-L1 antibody can play a synergistic antitumor effect. The combination of the two is a promising antitumor treatment strategy, which is expected to increase patients' response to immunotherapy and expand the range of potential beneficiaries. Currently, there is no product of a similar target approved for marketing domestically and overseas. The investigational new drug application for TAB006/JS006 injection was accepted by the National Medical Products Administration (the "NMPA") in November 2020, and was approved by the NMPA in January 2021. The Company will conduct the clinical trial in China according to the relevant requirements.